NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, today announced that management will participate in a fireside chat and host one-on-one investor meetings at the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024.
A webcast of the fireside chat at 1:30pm ET will be available on Talkspace’s Investor Relations Website: https://investors.talkspace.com/.
To schedule a one-on-one meeting with Talkspace, please reach out to your TD Cowen representative.
About Talkspace
Talkspace (Nasdaq: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall healthcare and should be available to everyone.
Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual and couples therapy, in addition to psychiatric treatment and medication management. With Talkspace’s core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including live video, text or audio chat sessions and/or asynchronous text messaging.
All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covers approximately 113 million lives as of September 30, 2023, through our partnerships with employers, health plans, and paid benefits programs.
For more information, visit www.talkspace.com.
Contacts
For Investors:
Neal Nagarajan
Sloane & Company
(301) 273-5662
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Media:
John Kim
SKDK
(310) 997-5963
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.04 |
| Daily Change: | -0.13 -4.10 |
| Daily Volume: | 2,048,192 |
| Market Cap: | US$511.360M |
October 29, 2024 September 04, 2024 August 06, 2024 July 24, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
